Loading data for XNCR — first visit, this takes a few seconds.
Xencor, Inc. (XNCR)
NasdaqGM: XNCR
· Real-Time Price · USD
24.41
+0.15 (0.62%)
At close: Sep 11, 2026, 8:00 PM
24.78
+1.52%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Xencor, Inc. (XNCR) Stock Price, Analysis & Data
No data available
| Bid | 14.35 |
| Market Cap | 1.81B |
| Revenue (ttm) | 105M |
| Net Income (ttm) | -163M |
| 0.88 | |
| -2.16 | |
| n/a | |
| -6.88 | |
| P/B (ttm) | 3.61 |
| P/S (ttm) | 17.29 |
| Earnings Date | Nov 4, 2026 |
| Ask | 25.39 |
| Volume | 898,630 |
| Avg. Volume (20D) | 1,179,206 |
| Open | 24.72 |
| Previous Close | 24.26 |
| Day's Range | 23.96 - 24.84 |
| 52-Week Range | 8.26 - 30.61 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About XNCR
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It al...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 3, 2013
Employees 260
Stock Exchange NasdaqGM
Ticker Symbol XNCR
Website https://www.xencor.com
Financial Performance
In 2025, Xencor's revenue was 125.58M, an increase of 13.65% compared to the previous year's 110.49M. Earnings were -91.92M, a decrease of -60.48%.
Financial StatementsEarnings Surprise
Xencor has released their quarterly earnings on Aug 5, 2026:
- Revenue of $51.22M misses estimates by $0, with 17.46% YoY growth.
- EPS of -0.29 exceeds estimates by 0.55, with 29.27% YoY growth.
Xencor, Inc. is scheduled to release its earnings on Nov 4, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2